{"created":"2023-05-15T16:50:10.524687+00:00","id":27923,"links":{},"metadata":{"_buckets":{"deposit":"437748bf-643c-4113-8fe9-181c74e2a4d4"},"_deposit":{"created_by":6,"id":"27923","owners":[6],"pid":{"revision_id":0,"type":"depid","value":"27923"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00027923","sets":["12:13"]},"author_link":["124518","124510","124500","124508","124506","124514","124501","124520","124503","124502","124509","124519","124498","124521","124499","124512","124511","124515","124507","124505","124516","124496","124497","124504","124513","124517"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2023-02-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3","bibliographicPageEnd":"e115","bibliographicPageStart":"e108","bibliographicVolumeNumber":"76","bibliographic_titles":[{"bibliographic_title":"Clinical Infectious Diseases"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background. Although several coronavirus disease 2019 (COVID-19) vaccines initially showed high efficacy, there have been concerns because of waning immunity and the emergence of variants with immune escape capacity.\nMethods. A test-negative design case-control study was conducted in 16 healthcare facilities in Japan during the Deltadominant period (August-September 2021) and the Omicron-dominant period (January-March 2022). Vaccine effectiveness (VE) against symptomatic severe acute respiratory syndrome coronavirus 2 infection was calculated for 2 doses for the Deltadominant period and 2 or 3 doses for the Omicron-dominant period compared with unvaccinated individuals.\nResults. The analysis included 5795 individuals with 2595 (44.8%) cases. Among vaccinees, 2242 (55.8%) received BNT162b2 and 1624 (40.4%) received messenger RNA (mRNA)-1273 at manufacturer-recommended intervals. During the Delta-dominant period, VE was 88% (95% confidence interval [CI], 82–93) 14 days to 3 months after dose 2 and 87% (95% CI, 38–97) 3 to 6 months after dose 2. During the Omicron-dominant period, VE was 56% (95% CI, 37–70) 14 days to 3 months since dose 2, 52% (95% CI, 40–62) 3 to 6 months after dose 2, 49% (95% CI, 34–61) 6+ months after dose 2, and 74% (95% CI, 62–83) 14+ days after dose 3. Restricting to individuals at high risk of severe COVID-19 and additional adjustment for preventive measures (ie, mask wearing/high-risk behaviors) yielded similar estimates, respectively.\nConclusions. In Japan, where most are infection-naïve, and strict prevention measures are maintained regardless of vaccination status, 2-dose mRNA vaccines provided high protection against symptomatic infection during the Delta-dominant period and moderate protection during the Omicron-dominant period. Among individuals who received an mRNA booster dose, VE recovered to a high level.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Clinical infectious diseases, 76(3), pp.e108-e115; 2023　","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Oxford University Press"}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1093/cid/ciac635","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com https://doi.org/10.1093/cid/ciac635"}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1058-4838","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Arashiro, Takeshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Arima, Yuzo"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Muraoka, Hirokazu"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Sato, Akihiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Oba, Kunihiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Uehara, Yuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Arioka, Hiroko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yanai, Hideki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kuramochi, Jin"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ihara, Genei"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Chubachi, Kumi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yanagisawa, Naoki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nagura, Yoshito"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kato, Yasuyuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ueda, Akihiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Numata, Akira"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kato, Hideaki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ishii, Koji"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ooki, Takao"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Oka, Hideaki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nishida, Yusuke"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Stucky, Ashley"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Smith, Chris"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hibberd, Martin"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ariyoshi, Koya"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Suzuki, Motoi"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2023-02-21"}],"displaytype":"detail","filename":"CID76_e108.pdf","filesize":[{"value":"682.5 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"CID76_e108.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/27923/files/CID76_e108.pdf"},"version_id":"0e0ae391-82f2-4594-ae77-be4c09ac89f6"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","subitem_subject_scheme":"Other"},{"subitem_subject":"coronavirus disease 2019 (COVID-19)","subitem_subject_scheme":"Other"},{"subitem_subject":"testnegative design","subitem_subject_scheme":"Other"},{"subitem_subject":"vaccine effectiveness","subitem_subject_scheme":"Other"},{"subitem_subject":"SARS-CoV-2 variants","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study)","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study)"}]},"item_type_id":"2","owner":"6","path":["13"],"pubdate":{"attribute_name":"公開日","attribute_value":"2023-02-21"},"publish_date":"2023-02-21","publish_status":"0","recid":"27923","relation_version_is_last":true,"title":["Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study)"],"weko_creator_id":"6","weko_shared_id":-1},"updated":"2023-05-15T18:13:16.072822+00:00"}